Amendments to the Claims:

1. (Currently Amended) A method for treating diabetic neuropathy ~~chronic pain~~ comprising administering to a patient in need of treatment an effective amount of a synergistic combination of a NK_1 receptor antagonist selected from [2-(1*H*-indol-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethylester [R-(R*,S*)] and (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine and a GABA analog selected from gabapentin and pregabalin.

2. (Original) A method of Claim 1 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.

3. (Original) A method according to Claim 1 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is 20:1 expressed as parts by weight.

4. (Original) A method according to Claim 1 wherein the NK_1 receptor antagonist is [2-(1*H*-indol-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethylester [R-(R*,S*)].

5. (Original) A method according to Claim 1 wherein the GABA analog is gabapentin.

6. (Original) A method according to Claim 1 wherein the GABA analog is pregabalin.

7. (Previously presented) A method according to Claim 1 employing [2-(1*H*-indol-3-yl)-l-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R*,S*)] and gabapentin.

8. (Currently Amended) A method according to Claim 1 employing [2-(1*H*-indol-3-yl)-l-methyl-l-(1 -phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ~~ylmethyl~~ ester[R-(R*,S*)] and pregabalin.

9. (Cancelled)

10. (Currently Amended) A pharmaceutical composition comprising synergistic effective amounts of a NK_1 receptor antagonist selected from [2-(1*H*-indol-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethylester [R-(R*,S*)] and (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine and a GABA analog selected from gabapentin and pregabalin.

11. (Original) A composition of Claim 10 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.

12. (Original) A composition of Claim 10 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is 20:1 expressed as parts by weight.

13. (Original) A composition of Claim 10 wherein the NK_1 receptor antagonist is [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)].

14. (Original) A composition of Claim 10 wherein the GABA analog is gabapentin.

15. (Original) A composition of Claim 10 wherein the GABA analog is pregabalin.

16. (Original) A composition of Claim 10 employing [2-(1*H*-indol-3-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and gabapentin.

17. (Original) A composition of Claim 1 employing [2-(1*H*-indol-3-yl)-l-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and pregabalin.

18. (Cancelled)

19. (New) A method according to Claim 1 wherein the NK_1 receptor antagonist is (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine.

20. (New) A method according to Claim 1 employing (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine and gabapentin.

21. (New) A method according to Claim 1 employing (2-(1*H*-indol-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl)-carbamic acid benzofuran-2-ylmethylester [R-(R*,S*)] and pregabalin.

22. (New) A composition of Claim 10 employing (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine and gabapentin.

23. (New) A composition of Claim 10 employing (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine and pregabalin.